Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease (2017)
Fonte: The New England Journal of Medicine. Unidade: FM
Assuntos: FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO, PLACEBO, DOENÇAS HEMATOLÓGICAS, EVENTO ADVERSO A MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ATAGA, Kenneth I. et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. The New England Journal of Medicine, v. 376, n. 5, p. 429-439, 2017Tradução . . Disponível em: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1611770. Acesso em: 16 maio 2024.APA
Ataga, K. I., Kutlar, A., Kanter, J., Liles, D., Cancado, R., Friedrisch, J., et al. (2017). Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. The New England Journal of Medicine, 376( 5), 429-439. doi:10.1056/NEJMoa1611770NLM
Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease [Internet]. The New England Journal of Medicine. 2017 ; 376( 5): 429-439.[citado 2024 maio 16 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1611770Vancouver
Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease [Internet]. The New England Journal of Medicine. 2017 ; 376( 5): 429-439.[citado 2024 maio 16 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1611770
